Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R.

Nature. 2019 Oct 2. doi: 10.1038/s41586-019-1607-3. [Epub ahead of print]

PMID:
31578521
2.

Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair.

van de Vrugt HJ, Harmsen T, Riepsaame J, Alexantya G, van Mil SE, de Vries Y, Bin Ali R, Huijbers IJ, Dorsman JC, Wolthuis RMF, Te Riele H.

Sci Rep. 2019 Jan 25;9(1):768. doi: 10.1038/s41598-018-36506-w.

3.

Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells.

Benedict B, van Harn T, Dekker M, Hermsen S, Kucukosmanoglu A, Pieters W, Delzenne-Goette E, Dorsman JC, Petermann E, Foijer F, Te Riele H.

Elife. 2018 Oct 16;7. pii: e37868. doi: 10.7554/eLife.37868.

4.

RNAi screening of subtracted transcriptomes reveals tumor suppression by taurine-activated GABAA receptors involved in volume regulation.

Wielders CLC, van Nierop P, Vormer TL, Foijer F, Verheij J, Lodder JC, Andersen JB, Mansvelder HD, Te Riele H.

PLoS One. 2018 May 22;13(5):e0196979. doi: 10.1371/journal.pone.0196979. eCollection 2018.

5.

DNA mismatch repair and oligonucleotide end-protection promote base-pair substitution distal from a CRISPR/Cas9-induced DNA break.

Harmsen T, Klaasen S, van de Vrugt H, Te Riele H.

Nucleic Acids Res. 2018 Apr 6;46(6):2945-2955. doi: 10.1093/nar/gky076.

6.

Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.

Rigter LS, Snaebjornsson P, Rosenberg EH, Atmodimedjo PN, Aleman BM, Ten Hoeve J, Geurts-Giele WR; PALGA group, van Ravesteyn TW, Hoeksel J, Meijer GA, Te Riele H, van Leeuwen FE, Dinjens WN, van Leerdam ME.

Gut. 2018 Mar;67(3):447-455. doi: 10.1136/gutjnl-2016-312608. Epub 2016 Nov 8.

PMID:
29439113
7.

Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.

Houlleberghs H, Goverde A, Lusseveld J, Dekker M, Bruno MJ, Menko FH, Mensenkamp AR, Spaander MCW, Wagner A, Hofstra RMW, Te Riele H.

PLoS Genet. 2017 May 22;13(5):e1006765. doi: 10.1371/journal.pgen.1006765. eCollection 2017 May.

8.

Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME.

BMC Cancer. 2017 Feb 7;17(1):112. doi: 10.1186/s12885-017-3089-8.

9.

Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.

Wielders E, Delzenne-Goette E, Dekker R, van der Valk M, Te Riele H.

Fam Cancer. 2017 Apr;16(2):221-229. doi: 10.1007/s10689-016-9945-x.

PMID:
27873144
10.

Genomic landscape of retinoblastoma in Rb-/- p130-/- mice resembles human retinoblastoma.

Kooi IE, van Mil SE, MacPherson D, Mol BM, Moll AC, Meijers-Heijboer H, Kaspers GJ, Cloos J, Te Riele H, Dorsman JC.

Genes Chromosomes Cancer. 2017 Mar;56(3):231-242. doi: 10.1002/gcc.22429. Epub 2016 Nov 21.

PMID:
27750399
11.

Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.

Kooi IE, Mol BM, Massink MP, Ameziane N, Meijers-Heijboer H, Dommering CJ, van Mil SE, de Vries Y, van der Hout AH, Kaspers GJ, Moll AC, Te Riele H, Cloos J, Dorsman JC.

Sci Rep. 2016 Apr 29;6:25264. doi: 10.1038/srep25264.

12.

A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression.

Kooi IE, Mol BM, Massink MP, de Jong MC, de Graaf P, van der Valk P, Meijers-Heijboer H, Kaspers GJ, Moll AC, Te Riele H, Cloos J, Dorsman JC.

PLoS One. 2016 Apr 26;11(4):e0153323. doi: 10.1371/journal.pone.0153323. eCollection 2016.

13.

LNA modification of single-stranded DNA oligonucleotides allows subtle gene modification in mismatch-repair-proficient cells.

van Ravesteyn TW, Dekker M, Fish A, Sixma TK, Wolters A, Dekker RJ, Te Riele HP.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4122-7. doi: 10.1073/pnas.1513315113. Epub 2016 Mar 7.

14.

Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.

Houlleberghs H, Dekker M, Lantermans H, Kleinendorst R, Dubbink HJ, Hofstra RM, Verhoef S, Te Riele H.

Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4128-33. doi: 10.1073/pnas.1520813113. Epub 2016 Mar 7.

15.

Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression.

Kooi IE, Mol BM, Moll AC, van der Valk P, de Jong MC, de Graaf P, van Mil SE, Schouten-van Meeteren AY, Meijers-Heijboer H, Kaspers GL, Te Riele H, Cloos J, Dorsman JC.

EBioMedicine. 2015 Jul 8;2(7):660-70. doi: 10.1016/j.ebiom.2015.06.022. eCollection 2015 Jul.

16.

Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients.

de Jong MC, Ten Hoeve JJ, Grénman R, Wessels LF, Kerkhoven R, Te Riele H, van den Brekel MW, Verheij M, Begg AC.

Clin Cancer Res. 2015 Dec 15;21(24):5630-8. doi: 10.1158/1078-0432.CCR-15-0454. Epub 2015 Aug 11. Erratum in: Clin Cancer Res. 2016 Jun 15;22(12):3118.

17.

Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma.

Scanu T, Spaapen RM, Bakker JM, Pratap CB, Wu LE, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, Song JY, Neefjes-Borst EA, te Riele H, Holden DW, Nath G, Neefjes J.

Cell Host Microbe. 2015 Jun 10;17(6):763-74. doi: 10.1016/j.chom.2015.05.002. Epub 2015 May 28.

18.

DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.

Stoepker C, Faramarz A, Rooimans MA, van Mil SE, Balk JA, Velleuer E, Ameziane N, Te Riele H, de Winter JP.

DNA Repair (Amst). 2015 Feb;26:54-64. doi: 10.1016/j.dnarep.2014.12.003. Epub 2014 Dec 24.

PMID:
25583207
19.

The retinoblastoma protein: multitasking to suppress tumorigenesis.

Vormer TL, Hansen JB, Te Riele H.

Mol Cell Oncol. 2015 Jan 26;2(1):e968062. doi: 10.4161/23723548.2014.968062. eCollection 2015 Jan-Mar.

20.

Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.

Wojciechowicz K, Cantelli E, Van Gerwen B, Plug M, Van Der Wal A, Delzenne-Goette E, Song JY, De Vries S, Dekker M, Te Riele H.

Gastroenterology. 2014 Nov;147(5):1064-72.e5. doi: 10.1053/j.gastro.2014.07.052. Epub 2014 Jul 31.

PMID:
25088490
21.

RB family tumor suppressor activity may not relate to active silencing of E2F target genes.

Vormer TL, Wojciechowicz K, Dekker M, de Vries S, van der Wal A, Delzenne-Goette E, Naik SH, Song JY, Dannenberg JH, Hansen JB, Te Riele H.

Cancer Res. 2014 Sep 15;74(18):5266-76. doi: 10.1158/0008-5472.CAN-13-3706. Epub 2014 Jul 23.

22.

Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.

Wielders EA, Hettinger J, Dekker R, Kets CM, Ligtenberg MJ, Mensenkamp AR, van den Ouweland AM, Prins J, Wagner A, Dinjens WN, Dubbink HJ, van Hest LP, Menko F, Hogervorst F, Verhoef S, te Riele H.

J Med Genet. 2014 Apr;51(4):245-53. doi: 10.1136/jmedgenet-2013-101987. Epub 2014 Feb 5.

PMID:
24501230
23.

Functional analysis in mouse embryonic stem cells reveals wild-type activity for three MSH6 variants found in suspected Lynch syndrome patients.

Wielders EA, Houlleberghs H, Isik G, te Riele H.

PLoS One. 2013 Sep 10;8(9):e74766. doi: 10.1371/journal.pone.0074766. eCollection 2013.

24.

SPO11-independent DNA repair foci and their role in meiotic silencing.

Carofiglio F, Inagaki A, de Vries S, Wassenaar E, Schoenmakers S, Vermeulen C, van Cappellen WA, Sleddens-Linkels E, Grootegoed JA, Te Riele HP, de Massy B, Baarends WM.

PLoS Genet. 2013 Jun;9(6):e1003538. doi: 10.1371/journal.pgen.1003538. Epub 2013 Jun 6.

25.

Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models.

Bakker ST, de Winter JP, te Riele H.

Dis Model Mech. 2013 Jan;6(1):40-7. doi: 10.1242/dmm.009795. Review.

26.

Tissue-specific mismatch repair protein expression: MSH3 is higher than MSH6 in multiple mouse tissues.

Tomé S, Simard JP, Slean MM, Holt I, Morris GE, Wojciechowicz K, te Riele H, Pearson CE.

DNA Repair (Amst). 2013 Jan 1;12(1):46-52. doi: 10.1016/j.dnarep.2012.10.006. Epub 2012 Nov 24.

PMID:
23228367
27.

Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor.

Tomosugi M, Sowa Y, Yasuda S, Tanaka R, te Riele H, Ikawa H, Koyama M, Sakai T.

Cancer Sci. 2012 Dec;103(12):2139-43. doi: 10.1111/cas.12012. Epub 2012 Oct 26.

28.

The mismatch repair system protects against intergenerational GAA repeat instability in a Friedreich ataxia mouse model.

Ezzatizadeh V, Pinto RM, Sandi C, Sandi M, Al-Mahdawi S, Te Riele H, Pook MA.

Neurobiol Dis. 2012 Apr;46(1):165-71. doi: 10.1016/j.nbd.2012.01.002. Epub 2012 Jan 20.

29.

Evidence for complete epistasis of null mutations in murine Fanconi anemia genes Fanca and Fancg.

van de Vrugt HJ, Koomen M, Bakker S, Berns MA, Cheng NC, van der Valk MA, de Vries Y, Rooimans MA, Oostra AB, Hoatlin ME, Te Riele H, Joenje H, Arwert F.

DNA Repair (Amst). 2011 Dec 10;10(12):1252-61. doi: 10.1016/j.dnarep.2011.09.015. Epub 2011 Oct 28.

PMID:
22036606
30.

Fancf-deficient mice are prone to develop ovarian tumours.

Bakker ST, van de Vrugt HJ, Visser JA, Delzenne-Goette E, van der Wal A, Berns MA, van de Ven M, Oostra AB, de Vries S, Kramer P, Arwert F, van der Valk M, de Winter JP, te Riele H.

J Pathol. 2012 Jan;226(1):28-39. doi: 10.1002/path.2992. Epub 2011 Nov 14.

PMID:
21915857
31.

Transient suppression of MLH1 allows effective single-nucleotide substitution by single-stranded DNA oligonucleotides.

Dekker M, de Vries S, Aarts M, Dekker R, Brouwers C, Wiebenga O, de Wind N, Cantelli E, Tonelli R, Te Riele H.

Mutat Res. 2011 Oct 1;715(1-2):52-60. doi: 10.1016/j.mrfmmm.2011.07.008. Epub 2011 Jul 27.

PMID:
21801734
32.

The mouse mismatch repair protein, MSH3, is a nucleoplasmic protein that aggregates into denser nuclear bodies under conditions of stress.

Holt I, Thanh Lam L, Tomé S, Wansink DG, Te Riele H, Gourdon G, Morris GE.

J Cell Biochem. 2011 Jun;112(6):1612-21. doi: 10.1002/jcb.23075.

PMID:
21344488
33.

Characterization of MSH2 variants by endogenous gene modification in mouse embryonic stem cells.

Wielders EA, Dekker RJ, Holt I, Morris GE, te Riele H.

Hum Mutat. 2011 Apr;32(4):389-96. doi: 10.1002/humu.21448. Epub 2011 Mar 8.

PMID:
21309037
34.

Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations.

Johannesma PC, van der Klift HM, van Grieken NC, Troost D, Te Riele H, Jacobs MA, Postma TJ, Heideman DA, Tops CM, Wijnen JT, Menko FH.

Clin Genet. 2011 Sep;80(3):243-55. doi: 10.1111/j.1399-0004.2011.01635.x. Epub 2011 Feb 20.

PMID:
21261604
35.

Progress and prospects: oligonucleotide-directed gene modification in mouse embryonic stem cells: a route to therapeutic application.

Aarts M, te Riele H.

Gene Ther. 2011 Mar;18(3):213-9. doi: 10.1038/gt.2010.161. Epub 2010 Dec 16. Review.

PMID:
21160530
36.

Azathioprine-induced carcinogenesis in mice according to Msh2 genotype.

Chalastanis A, Penard-Lacronique V, Svrcek M, Defaweux V, Antoine N, Buhard O, Dumont S, Fabiani B, Renault I, Tubacher E, Fléjou JF, Te Riele H, Duval A, Muleris M.

J Natl Cancer Inst. 2010 Nov 17;102(22):1731-40. doi: 10.1093/jnci/djq389. Epub 2010 Oct 5.

37.

The APC/C recruits cyclin B1-Cdk1-Cks in prometaphase before D box recognition to control mitotic exit.

van Zon W, Ogink J, ter Riet B, Medema RH, te Riele H, Wolthuis RM.

J Cell Biol. 2010 Aug 23;190(4):587-602. doi: 10.1083/jcb.200912084.

38.

Subtle gene modification in mouse ES cells: evidence for incorporation of unmodified oligonucleotides without induction of DNA damage.

Aarts M, te Riele H.

Nucleic Acids Res. 2010 Nov;38(20):6956-67. doi: 10.1093/nar/gkq589. Epub 2010 Jul 2.

39.

Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling.

van Harn T, Foijer F, van Vugt M, Banerjee R, Yang F, Oostra A, Joenje H, te Riele H.

Genes Dev. 2010 Jul 1;24(13):1377-88. doi: 10.1101/gad.580710. Epub 2010 Jun 15.

40.

Parameters of oligonucleotide-mediated gene modification in mouse ES cells.

Aarts M, te Riele H.

J Cell Mol Med. 2010 Jun;14(6B):1657-67. doi: 10.1111/j.1582-4934.2009.00847.x. Epub 2009 Jul 20.

41.

Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M.

Bakker ST, van de Vrugt HJ, Rooimans MA, Oostra AB, Steltenpool J, Delzenne-Goette E, van der Wal A, van der Valk M, Joenje H, te Riele H, de Winter JP.

Hum Mol Genet. 2009 Sep 15;18(18):3484-95. doi: 10.1093/hmg/ddp297. Epub 2009 Jun 26.

PMID:
19561169
42.

Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination.

Ferrás C, Oude Vrielink JA, Verspuy JW, te Riele H, Tsaalbi-Shtylik A, de Wind N.

Mol Ther. 2009 Aug;17(8):1373-80. doi: 10.1038/mt.2009.114. Epub 2009 May 26.

43.

Recreating stem cells: a novel entrance to the fountain of youth.

te Riele H.

Cell Stem Cell. 2009 Apr 3;4(4):279-80. doi: 10.1016/j.stem.2009.03.011.

44.

Anchorage-independent growth of pocket protein-deficient murine fibroblasts requires bypass of G2 arrest and can be accomplished by expression of TBX2.

Vormer TL, Foijer F, Wielders CL, te Riele H.

Mol Cell Biol. 2008 Dec;28(24):7263-73. doi: 10.1128/MCB.00313-08. Epub 2008 Oct 20.

45.

Retinoblastoma teaches a new lesson.

te Riele H.

Cell. 2007 Oct 19;131(2):227-9.

46.

In vivo significance of the G2 restriction point.

Foijer F, Delzenne-Goette E, Dekker M, Te Riele H.

Cancer Res. 2007 Oct 1;67(19):9244-7.

47.

Oncogenic pathways impinging on the G2-restriction point.

Foijer F, Simonis M, van Vliet M, Wessels L, Kerkhoven R, Sorger PK, Te Riele H.

Oncogene. 2008 Feb 14;27(8):1142-54. Epub 2007 Aug 13.

PMID:
17700522
48.

Generation of a mouse mutant by oligonucleotide-mediated gene modification in ES cells.

Aarts M, Dekker M, de Vries S, van der Wal A, te Riele H.

Nucleic Acids Res. 2006;34(21):e147. Epub 2006 Nov 16.

49.

The retinoblastoma gene family in cell cycle regulation and suppression of tumorigenesis.

Dannenberg JH, te Riele HP.

Results Probl Cell Differ. 2006;42:183-225. Review.

PMID:
16903212
50.

Supplemental Content

Loading ...
Support Center